Technology
Pipeline
Intranasal Naloxone
Intranasal Epinephrine
About us
Contact
News
Investors
Overview
Press Releases
Events
SEC Filings
Corporate Governance
Stock Information
FAQs
Menu
Technology
Pipeline
Intranasal Naloxone
Intranasal Epinephrine
About us
Contact
News
Investors
Overview
Press Releases
Events
SEC Filings
Corporate Governance
Stock Information
FAQs
Nasus Pharma Announces Publication Of Its Positive Clinical Results With FMXIN002 Intranasal Powder Epinephrine Spray In The Journal Of Allergy And Clinical Immunology In Practice
CLICK HERE
Share this post
Previous
Nasus pharma presented clinical results at Fourth Annual – ASPN Conference, July 14-17, Miami Beach
Next
Nasus Pharma Announces Positive Clinical Results of Recent Phase 2 Study With FMXIN002 Intranasal Epinephrine